Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
Regulation of Hematopoietic Stem Cells01:01

Regulation of Hematopoietic Stem Cells

All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The role of impaired bone marrow Tregs in hematopoietic stem cell depletion for pediatric aplastic anemia probably involves immune privilege.

Blood research·2026
Same author

Correction: Prevalence, mutation distribution, and economic burden of thalassemia in China: a systematic review and regional analysis.

Archives of public health = Archives belges de sante publique·2026
Same author

The impact of m6A modified cargo conveyed by exosomes on the tumor microenvironment.

Discover oncology·2026
Same author

IL-1-mediated vitreous inflammation as an early indicator of retinal ganglion cell loss following acute optic nerve injury.

Journal of neuroinflammation·2026
Same author

Serial passaging <i>in vitro</i> generates a Vero cell-adapted coxsackievirus A6 strain with distinct phenotypic characteristics.

Frontiers in cellular and infection microbiology·2026
Same author

Vis-OCT Explorer: an open-source software for visible-light optical coherence tomography data processing.

Biomedical optics express·2026

Related Experiment Video

Updated: Jul 12, 2026

Intrafemoral Injection of Human Hematopoietic Stem and Progenitor Cells into Immunocompromised Mice
03:40

Intrafemoral Injection of Human Hematopoietic Stem and Progenitor Cells into Immunocompromised Mice

Published on: December 8, 2023

Optimising Haematopoietic Stem Cell Transplantation: Enhancing Myeloablation Sensitivity and Alleviating Anaemia

Guanheng Yang1,2,3, Jiahui Wu1,3, Xinbing Guo1,3

  • 1Shanghai Institute of Medical Genetics, Shanghai Children's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.

Cell Proliferation
|July 10, 2026
PubMed
Summary

Roxadustat (FG-4592) enhances bone marrow conditioning for haematopoietic stem cell transplantation (HSCT). This improves donor cell engraftment and hematologic recovery, offering a potential adjuvant therapy for various diseases.

Keywords:
Roxadustat (FG‐4592)bone marrow microenvironmenthaematopoietic stem cellmyeloablationthalassaemiatransplantation

More Related Videos

CRISPR/Cas9 Gene Editing of Hematopoietic Stem and Progenitor Cells for Gene Therapy Applications
08:32

CRISPR/Cas9 Gene Editing of Hematopoietic Stem and Progenitor Cells for Gene Therapy Applications

Published on: August 9, 2022

Related Experiment Videos

Last Updated: Jul 12, 2026

Intrafemoral Injection of Human Hematopoietic Stem and Progenitor Cells into Immunocompromised Mice
03:40

Intrafemoral Injection of Human Hematopoietic Stem and Progenitor Cells into Immunocompromised Mice

Published on: December 8, 2023

CRISPR/Cas9 Gene Editing of Hematopoietic Stem and Progenitor Cells for Gene Therapy Applications
08:32

CRISPR/Cas9 Gene Editing of Hematopoietic Stem and Progenitor Cells for Gene Therapy Applications

Published on: August 9, 2022

Area of Science:

  • Hematology
  • Cellular Biology
  • Pharmacology

Background:

  • Haematopoietic stem cell transplantation (HSCT) is crucial for treating hematologic, autoimmune, and genetic diseases.
  • Effective HSCT relies on myeloablation to clear bone marrow space for donor cells.
  • Standard busulfan and cyclophosphamide (BuCy) conditioning can be toxic and may not fully eliminate recipient cells.

Purpose of the Study:

  • To investigate if co-administering Roxadustat (FG-4592) with BuCy conditioning improves myeloablation efficiency and donor-cell engraftment.
  • To assess the impact of FG-4592 on recipient cell depletion and donor cell engraftment.
  • To evaluate FG-4592's effects on hematologic recovery and iron metabolism in a disease model.

Main Methods:

  • Investigated the effect of FG-4592 co-administration during BuCy conditioning in a preclinical HSCT model.
  • Assessed the sensitivity of bone marrow mononuclear cell (BM-MNC) populations to BuCy conditioning with and without FG-4592.
  • Evaluated donor-cell engraftment, hematologic recovery, and splenic iron deposition in β654 thalassaemia mice post-HSCT.

Main Results:

  • FG-4592 increased the sensitivity of BM-MNCs to BuCy, leading to deeper depletion of recipient cells.
  • Improved clearance of recipient cells facilitated enhanced donor-cell residency and engraftment.
  • In β654 thalassaemia mice, FG-4592 treatment alleviated anemia and reduced splenic iron deposition after HSCT.

Conclusions:

  • FG-4592 acts as an effective adjuvant to standard BuCy myeloablation, enhancing conditioning efficiency.
  • This approach supports improved donor-cell engraftment and hematologic recovery post-HSCT.
  • This study is the first to demonstrate that a hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor can improve HSCT conditioning efficacy.